Gueorgui Gueorguiev
Morrison, ILNPI 1790719243
Payments from drug & device makers
Across 72 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$205
- Amgen$127
- AstraZeneca$126
- Pfizer$124
- Novo Nordisk$59
- Lilly USA, LLC$58
- plus $496 from 21 others
What the payments were for
- Food & beverage$1,195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $205 |
| Amgen | 8 | $127 |
| AstraZeneca | 8 | $126 |
| Pfizer | 8 | $124 |
| Novo Nordisk | 4 | $59 |
| Lilly USA, LLC | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $49 |
| Boehringer Ingelheim | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Baudax Bio Inc. | 2 | $28 |
| Harmony Biosciences LLC | 1 | $25 |
| Vertex | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Organon | 2 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Organogenesis Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $13,624 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $6,849 |
| Fluocinonide | 43 | $3,172 |
| Imiquimod | 30 | $2,557 |
| Omeprazole | 80 | $1,105 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,098 |
| Atorvastatin Calcium | 117 | $972 |
| Lisinopril | 110 | $901 |
| Misoprostol | 11 | $869 |
| Levothyroxine Sodium | 98 | $818 |
| Minocycline Hcl | 17 | $643 |
| Gabapentin | 36 | $593 |
| Triamcinolone Acetonide | 16 | $585 |
| Amlodipine Besylate | 101 | $566 |
| Losartan Potassium | 52 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $59 | $13,62413 claims |
| AstraZenecaSymbicort | $126 | $6,84927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Illinoison file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.